Category: Today’s Highlights

At bluebird bio an Investigational Gene Therapy is Demonstrating Promising Results

At bluebird bio an Investigational Gene Therapy is Demonstrating Promising Results

bluebird bio Has Promising Results from Its Lenti-D Gene Therapy for CALD Good results have come from bluebird bio’s (BLUE) updated results in the clinical development program for its investigational Lenti-D™ gene therapy in patients with cerebral adrenoleukodystrophy (CALD) at the 13th European Pediatric Neurology Society (EPNS) Congress in Athens, Greece. bluebird bio's Starbeam Trial . . . This content is for paid subscribers. Please click here to subscribe or here to …
Why Alder Biopharmaceuticals Stock Gained Over 83%. See Also: Prohost Picked Stocks Outperforming in a Down Market Day

Why Alder Biopharmaceuticals Stock Gained Over 83%. See Also: Prohost Picked Stocks Outperforming in a Down Market Day

Migraine's Really Effective Treatments The years 2018 and 2019 could be called the years of migraine’s really effective treatments. Three Calcitonin-gene-related peptide (CGRP) monoclonal antibody drugs have been approved in 2018 and 2019. They are: Aimovig for Amgen (AMGN . . . This content is for paid subscribers. Please click here to subscribe or here to log in.
About RegenxBio’s Agreement with Clearside Biomedical and More

About RegenxBio’s Agreement with Clearside Biomedical and More

Diseases of the Back of the Eye Diseases of the back of the eye, such as: age-related wet macular degeneration, diabetic retinopathy and diabetic macular edema, are currently managed with injections of anti-vascular endothelial growth factor (anti-VEGF) drugs into the gel-like substance (the vitreous humor) that fills the eye between the lens and the retina. The currently used age-related wet macular degeneration injections are: Lucentis, which belongs …
Amgen’s Oncology Product AMG-510 Meeting An Unmet Need for Kras G12C Mutated Cancers

Amgen’s Oncology Product AMG-510 Meeting An Unmet Need for Kras G12C Mutated Cancers

Amgen's Outperforming After being boxed in, for the past couple of weeks, Amgen’s (AMGN) stock finally outperformed. The firm was outperforming silently with regard to its financial results, sciences, technologies, pipeline products and multiple newly approved products drugs.   In the News Amgen's Product AMG-510 Amgen announced new data from its ongoing Phase 1 study evaluating its unique cancer product AMG . . . This content …
Vertex: In Pursuit of Cures

Vertex: In Pursuit of Cures

Vertex Pharmaceuticals Is Acquiring Semma Therapeutics Vertex Pharmaceutical (VRTX) entered into a definitive agreement to buy a private company, Semma Therapeutics. Semma uses stem cell-derived human islets as a potential cure for type 1 diabetes. Semma’s major scientific advances include: an ability to produce large quantities of functional human pancreatic beta cells that could . . . This content is for paid subscribers. Please click here to subscribe …
Gene Therapy and Other Treatments That Work at the Genetic Level

Gene Therapy and Other Treatments That Work at the Genetic Level

Gene Therapy Stocks Experiencing Selloffs  Every investor in the biotech sector must have experienced selloffs of the stocks from companies specialized in gene therapy, gene editing, antisense, RNAi and mRNA therapies. Recently, bluebird bio’s (BLUE) stock was devastated. The selloffs occurred for many reasons, most of . . . This content is for paid subscribers. Please click here to subscribe or here to log in.
The Medicines Company Has Agreeable News

The Medicines Company Has Agreeable News

The Medicines Company The Medicines Company (MDCO) focuses on cardiovascular diseases. Major goals are halting the progression of atherosclerosis and lowering the cardiovascular risk caused by high levels of LDL Cholesterol (LDL-C). The firm announced good news from the results of its first pivotal Phase . . . This content is for paid subscribers. Please click here to subscribe or here to log in.
Regeneron: Successful Cure for Ebola-Infected People. Read Also: The Midday Outperforming Biotech Stocks

Regeneron: Successful Cure for Ebola-Infected People. Read Also: The Midday Outperforming Biotech Stocks

Regeneron Product REGN-EB3 Saving Lives Regeneron (REGN) announced that an independent monitoring board ended its investigational product REGN-EB3 trial after reviewing interim mortality data from 499 patients. REGN-EB3 was found superior to rival therapy from Mapp Biopharmaceuticals (MAPP) in saving the lives in . . . This content is for paid subscribers. Please click here to subscribe or here to log in.
Nektar’s Story Has Nothing to Do with the Efficacy Or the Value of NKTR-214

Nektar’s Story Has Nothing to Do with the Efficacy Or the Value of NKTR-214

Nektar Therapeutics Story Everything was going well with Nektar Therapeutics (NKTR) stock during the Conference call regarding the firm’s Q2 financial results. (See the firm's press release under our Impacting News column). Following the Conference call the company unveiled that some of the patients treated in . . . This content is for paid subscribers. Please click here to subscribe or here to log in.
Unveiled Good News About Prohost Picked Biotech Stocks

Unveiled Good News About Prohost Picked Biotech Stocks

 The News Prohost Was Waiting for to Post Its Special Letter Prohost has one eye on the development-stage biotech and biopharmaceutical companies' scientific fundamentals and accomplishments as well as the financial results on the revenue-generating firms. Prohost has the second eye on the market performance, its volatility and the possible reasons it sinks every other day, or every other week, in calmer days during a …
What We Learned from Yesterday’s and Today’s Stocks’ Moves

What We Learned from Yesterday’s and Today’s Stocks’ Moves

What Have We Learned from the Market's Recent Stock Moves? Well. Did we learn anything from what happened in the stock market and the reversal that started near the end of yesterday and occurred today? Listening to Larry Kudlow, the Director of the National Economic Council, as well as other academic economists and analysts all the while watching the way the market crashed yesterday and …
An Important Statement to Prohost Readers

An Important Statement to Prohost Readers

Prohost has just finished a very hard task; evaluating its best picks from the biotechnology and biopharmaceutical sectors. In this evaluation of hand-selected stocks, Prohost did not consider the negotiation between the U.S. and China a serious factor that could affect the biotech stocks’ values. We do, however, consider the US/China negotiations extremely important towards reaching a fair solution that satisfies the people in both …
The Nektar Good News Cannot be Hidden Any Longer

The Nektar Good News Cannot be Hidden Any Longer

Nektar Therapeutics We believe that Nektar Therapeutics (NKTR) is undervalued. We base this on the firm’s technological capability. Its current pipeline is filled with promising products. Today we learned that the U.S. FDA granted Nektar’s and Bristol-Myers Squibb’s . . . This content is for paid subscribers. Please click here to subscribe or here to log in.
Why We Decided Not To Abandon the Amgen and Illumina Band Wagons

Why We Decided Not To Abandon the Amgen and Illumina Band Wagons

Amgen Contrary to our expectations Amgen’s (AMGN) shares declined more than 10% in 2019, instead of rallying. Part of the decline followed the threat of devastating the large drug creators and developers by lowering the high prices of drugs. Amgen’s stock loss can also be attributed to the pressure exerted by negative investors on the stock.   Today, after . . . This content is for …
Gilead Sciences Activities Are Exceeding Its All Time High. Celgene Demonstrates How Valuable It Could be for Bristol-Myers Squibb.

Gilead Sciences Activities Are Exceeding Its All Time High. Celgene Demonstrates How Valuable It Could be for Bristol-Myers Squibb.

Gilead Sciences Activities There is no doubt that Gilead Sciences (GILD) is doing whatever it takes to expand, improve and upgrade its pipeline products. For the last couple of months, each and every week, we heard news about collaborations with some companies and investment in others as well as licensing products from large, medium-sized and small firms. In less than ten . . . This content is for …
Seattle Genetics Deserves Its Stock Rally

Seattle Genetics Deserves Its Stock Rally

Seattle Genetics Stock Rallied Seattle Genetics (SGEN) financial results started with Clay Siegall, Ph.D., President and Chief Executive Officer of the firm stating the following: Seattle Genetics achieved record net sales in the U.S. and Canada for Adcetris, reflecting growth in frontline CD30-expressing peripheral T-cell lymphomas as well as frontline advanced Hodgkin lymphoma.   The Biologics . . . This content is for paid subscribers. Please …
Takeda: Advancing the Potential for Off-the-Shelf, Highly Scalable and Lower Cost CAR T-Cell Therapy for Cancer Treatment.

Takeda: Advancing the Potential for Off-the-Shelf, Highly Scalable and Lower Cost CAR T-Cell Therapy for Cancer Treatment.

CiRA, Takeda & T-CiRA Less than five years ago the Center for iPS Cell Research and Application (CiRA)1 at Kyoto University and Takeda Pharmaceutical (TAK)2 established a research program. Today, Takeda and CiRA announced that induced pluripotent stem cell-derived chimeric antigen receptor (CAR) T-cell therapy (iCART . . . This content is for paid subscribers. Please click here to subscribe or here to log in.
Exelixis: Encouraging Results from Cabozantinib Trial and a Good Decision by the Firm

Exelixis: Encouraging Results from Cabozantinib Trial and a Good Decision by the Firm

Exelixis is Expanding Cohorts for COSMIC-021, the Phase 1b Trial for Cabozantinib  From Exelixis (EXEL) we learned about its decision to expand the two original cohorts, and the addition of four new cohorts, to the protocol for COSMIC-021; the phase 1b trial of cabozantinib (CABOMETYX®) in combination with atezolizumab (TECENTRIQ®) in patients with locally advanced or . . . This content is for paid subscribers. …
Are Illumina’s 2019 Challenges Transitory?

Are Illumina’s 2019 Challenges Transitory?

Illumina Stock Dropped Following Their Preliminary Revenue Announcement Illumina (ILMN) stock dropped 16% following the firm's announcement of preliminary revenue for the second quarter of the fiscal year 2019 and updated its 2019 revenue guidance. According to the firm’s press release its second quarter results were impacted by an approximately $30 million lower revenue than expected; associated with population genomics initiatives, including a sizeable sequencing . …